Stockscreener 앱 받기
49.28
25.79%
-17.13
시간 외 거래:
49.00
-0.28
-0.57%
전일 마감가:
$66.41
열려 있는:
$53.51
하루 거래량:
88.55M
Relative Volume:
5.02
시가총액:
$10.77B
수익:
$1.24B
순이익/손실:
$101.26M
주가수익비율:
112.00
EPS:
0.44
순현금흐름:
$149.62M
1주 성능:
-18.51%
1개월 성능:
+65.31%
6개월 성능:
+197.40%
1년 성능:
+423.70%
1일 변동 폭
$49.05
$57.37
1주일 범위
$49.05
$72.98
52주 변동 폭
$9.25
$72.98
Hims Hers Health Inc Stock (HIMS) Company Profile
명칭
Hims Hers Health Inc
전화
415-851-0195
주소
2269 CHESTNUT ST, SAN FRANCISCO
HIMS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
49.28 | 10.77B | 1.24B | 101.26M | 149.62M | 0.44 |
|
PG
Procter Gamble Co
|
170.23 | 399.16B | 84.35B | 15.48B | 15.47B | 6.28 |
|
UL
Unilever Plc Adr
|
56.13 | 141.20B | 65.10B | 6.16B | 0 | 2.4569 |
|
CL
Colgate Palmolive Co
|
89.47 | 73.10B | 20.10B | 2.89B | 3.55B | 3.52 |
|
KMB
Kimberly Clark Corp
|
140.26 | 46.52B | 20.06B | 2.55B | 2.51B | 7.55 |
|
KVUE
Kenvue Inc
|
23.32 | 44.71B | 15.46B | 1.03B | 1.40B | 0.53 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2025-01-07 | 개시 | BTIG Research | Buy |
| 2024-12-17 | 개시 | Morgan Stanley | Overweight |
| 2024-11-14 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2024-08-22 | 개시 | Needham | Buy |
| 2024-08-09 | 다운그레이드 | Imperial Capital | Outperform → In-line |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-04-16 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-04-10 | 개시 | Canaccord Genuity | Buy |
| 2024-02-28 | 업그레이드 | Imperial Capital | In-line → Outperform |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2023-12-07 | 개시 | Imperial Capital | In-line |
| 2023-07-28 | 개시 | TD Cowen | Outperform |
| 2023-04-11 | 개시 | Robert W. Baird | Neutral |
| 2023-02-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-11-08 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | 개시 | Truist | Hold |
| 2022-07-15 | 개시 | SVB Leerink | Underperform |
| 2022-04-14 | 개시 | Guggenheim | Buy |
| 2022-04-01 | 재개 | Credit Suisse | Outperform |
| 2022-03-10 | 개시 | Deutsche Bank | Hold |
| 2021-12-02 | 개시 | Jefferies | Hold |
| 2021-11-11 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | 개시 | BofA Securities | Neutral |
| 2021-05-20 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | 개시 | Truist | Hold |
| 2021-03-09 | 개시 | Credit Suisse | Neutral |
| 2021-03-02 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-02-17 | 개시 | Citigroup | Neutral |
| 2021-02-12 | 개시 | Piper Sandler | Neutral |
| 2021-02-08 | 개시 | Tigress Financial | Buy |
모두보기
Hims Hers Health Inc 주식(HIMS)의 최신 뉴스
Hims & Hers falls, Novo Nordisk rises after FDA says Ozempic shortage is over - Sherwood News
Hims & Hers shares dive on end of weight loss drug shortage - Yahoo Finance
U.S. Markets Dropped Friday; Hims & Hers Health Fell Furthest - Barron's
Hims & Hers Stock Plummets. The Wegovy Shortage Is Over. - Barron's
Hims & Hers Stock Falls as FDA Resolves Semaglutide ShortageNews and Statistics - IndexBox, Inc.
Why Hims & Hers Health (HIMS) Shares Are Getting Obliterated Today - Yahoo Finance
Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers - Fortune
Why Hims & Hers Health Stock Is Plummeting Today - The Motley Fool
Why Hims & Hers Stock Dropped Today - MSN
Why Hims & Hers Health Stock Is Skyrocketing Today - AOL
Hims & Hers Stock Hits Record High on Blood-Testing Lab Acquisition - MSN
FDA says Ozempic and Wegovy shortage is ending. That’s bad news for this wellness stock. - MarketWatch
Piper Sandler maintains Neutral on Hims & Hers stock, target at $24 - Investing.com India
Sector Update: Health Care - TradingView
Hims & Hers Buys Lab to Expand Into At-Home Blood Testing - MSN
Why Hims & Hers Health, Inc. (HIMS) Went Up On Wednesday? - MSN
Why Is HIMS Stock Dropping Today? - Markets Insider
Hims & Hers' stock plunges as semaglutide shortage ends - Modern Healthcare
UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More Movers - Barron's
Analysts explain why Hims & Hers stock is crashing today - Investing.com
Hims and Hers Stock Drops Weight as Earnings Loom - Schaeffers Research
Hims & Hers Stock: More Gains Ahead Or A Pullback? Most Retail Traders Bet On This Path - MSN
What's Going On With Hims & Hers Health Stock Today? - Benzinga
BofA keeps Hims & Hers stock underperform, $21 target - Investing.com
Hims & Hers: A Glorious Opportunity To Trim (Rating Downgrade) (NYSE:HIMS) - Seeking Alpha
Hims & Hers Stock Falls 19% Following FDA Update on Ozempic and Wegovy - Yahoo Finance
Hims & Hers Health (NYSE:HIMS) Sees Strong Trading Volume on Analyst Upgrade - MarketBeat
FDA gives compounders short reprieve as Novo Nordisk GLP-1 supply normalizes - Seeking Alpha
Hims & Hers Crashes 22%--But Its Secret Power Move Could Change Everything - Yahoo Finance UK
Hims & Hers acquires peptide facility to boost drug manufacturing - Modern Healthcare
Hims & Hers Health Shares Fall Pre-Bell as US FDA Says Ozempic, Wegovy Shortages Have Ended - Marketscreener.com
Hims & Hers Health Acquires California Peptide Facility -February 21, 2025 at 09:40 am EST - Marketscreener.com
Hims & Hers Health stock falls as FDA ends drug shortage - Investing.com
Hims & Hers acquires California peptide facility - Investing.com India
Hims & Hers gains peptide facility; shares tumble on semaglutide shortage end (HIMS:NYSE) - Seeking Alpha
Hims & Hers stock falls as Ozempic shortage ends (HIMS:NYSE) - Seeking Alpha
Hims & Hers Acquires US-Based Peptide Facility -February 21, 2025 at 09:02 am EST - Marketscreener.com
Why Hims & Hers Health (HIMS) Is Rallying Today - MSN
Hims & Hers Acquires US-based Peptide Facility - Joplin Globe
Hims Expands Drug Manufacturing With California Peptide Plant Acquisition - Bloomberg
Hims & Hers Hits New Highs On At-Home Lab Testing Plans: Retail Sees More Room To Run, Analysts Divided - MSN
Bank of America Forecasts Strong Price Appreciation for Hims & Hers Health (NYSE:HIMS) Stock - MarketBeat
Gilead's new HIV med, a bird flu shot for chickens, and Hims does blood tests: Pharma news roundup - Quartz
Hims & Hers: From Viral Ad to Volatile Stock - MSN
Hims & Hers: After A 205% Gain, Downgrading To A Hold, But Options Present An Opportunity - Seeking Alpha
Hims & Hers Health's chief commercial officer sells $444,450 in stock - Investing.com
Hims & Hers health chief legal officer sells $251,984 in stock - Investing.com
Unlocking HIMS Stock’s Secrets: How Innovations Propel a Surprise Surge - Reporteros del Sur -
Hims & Hers CEO Andrew Dudum sells $10.2 million in stock - Investing.com India
Hims & Hers Health, Inc. (NYSE:HIMS) Insider Soleil Boughton Sells 4,152 Shares - MarketBeat
Hims & Hers Health (NYSE:HIMS) Trading Down 5.9%Here's Why - MarketBeat
Hims Hers Health Inc (HIMS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.06%
자본화:
|
볼륨(24시간):